A5055741970- Medication Adherence and Compliance
- Pharmaceutical Practices and Patient Outcomes
- Economic and Financial Impacts of Cancer
- Health Systems, Economic Evaluations, Quality of Life
- Cancer Treatment and Pharmacology
- Cancer survivorship and care
- Neutropenia and Cancer Infections
- Pharmaceutical studies and practices
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Childhood Cancer Survivors' Quality of Life
- Chronic Lymphocytic Leukemia Research
- Chemotherapy-related skin toxicity
- Bacterial Identification and Susceptibility Testing
- Antimicrobial Resistance in Staphylococcus
- Antifungal resistance and susceptibility
- Pneumocystis jirovecii pneumonia detection and treatment
- Bipolar Disorder and Treatment
- Fungal Infections and Studies
- Palliative Care and End-of-Life Issues
- Chronic Myeloid Leukemia Treatments
- Pharmaceutical Economics and Policy
- Nausea and vomiting management
- Advanced Breast Cancer Therapies
- Medical and Biological Ozone Research
- Lymphatic System and Diseases
University of Michigan
2010-2025
VA Center for Clinical Management Research
2022-2025
Michigan Cancer Research Consortium
2014-2025
Michigan Medicine
2007-2024
Virginia Commonwealth University
2018
University Health System
2017
Stanford Cancer Institute
2017
Cancer Prevention Institute of California
2017
Ann Arbor Center for Independent Living
2015
American Society of Clinical Oncology
2015
Patients with cancer are at increased risk for developing infectious complications during the course of their disease and treatment. The following sections NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Prevention Treatment Cancer-Related Infections provide an overview factors complications, recommendations categorization, strategies prevention infections high-risk patient populations cancer. Individualized evaluation incorporation preventative measures essential components...
PURPOSE: The aim of the current work was to present a pharmacy practice standard from Hematology/Oncology Pharmacy Association (HOPA) on management oral oncolytic therapy. METHODS: HOPA Standards Committee organized group oncology pharmacist specialists create for therapy that describes pharmacist’s role cancer care team, provides examples tools and resources, summarizes data related outcomes, discusses opportunities enhance patients with who receive We reviewed primary literature, including...
Abstract Introduction Ambulatory care pharmacists can help overcome systemic barriers in diabetes management for American Indians and Alaska Natives (AI/AN) by facilitating the adoption of continuous glucose monitoring (CGM) technology. Despite proven clinical benefits CGM, its use AI/AN populations remains limited underexplored. The aim this study was to evaluate impact a pharmacist‐driven CGM program on glycemic control patients with characterize implementation intervention practice....
Managing patients who are taking oral oncolytics is challenging because of the changing paradigm from frequent supervision during intravenous therapy to periodic observation with administration drugs. We joined Michigan Oncology Quality Consortium (MOQC) Oral Oncolytics Collaborative in 2013 identify opportunities for improvement this area.We completed MOQC's baseline self-assessment and performed an audit medical records 25 prescribed oncolytic May 2011 July 2013. implemented following MOQC...
PURPOSE The Hematology Oncology Pharmacist Association Oral Chemotherapy Collaborative (HOPA OCC) developed practice-based tools to use in program development and improvement for the management of patients receiving oral anticancer agents (OAAs). METHODS These include a baseline OAA assessment, clinical adherence tool, dashboard. HOPA OCC distributed these teams participating 6-month ASCO Quality Training Programs (QTPs). Barriers delivery services across practice sites were determined...
Clinical trials inform cancer care, yet real-world outcomes often diverge due to patient-related factors, like age, organ dysfunction, and nonadherence oral anticancer agents (OAAs). While oncology organizations emphasize patient support programs, practical guidance on designing implementing these programs is limited. We conducted a two-phase, mixed-methods study enhance the adoption, implementation, sustainability of an OAA adherence program (OAP). In phase 1, we used implementation mapping...
Importance Olanzapine as part of a 4-drug antiemetic regimen is highly effective at preventing nausea and vomiting in patients receiving emetogenic chemotherapy (HEC). National prescribing rates olanzapine eligible have, however, remained persistently low. Objective To describe efforts to increase the guideline-concordant use HEC statewide oncology collaborative. Design, Setting, Participants The Michigan Oncology Quality Consortium (MOQC) collaborative Michigan-based practices whose mission...
The collection of oral chemotherapy test measure data is feasible, and improvement opportunities exist for patients who are prescribed chemotherapy.
REMS are a particularly important issue for oncology and the National Comprehensive Cancer Network (NCCN). A disproportionate number of drugs with complex used in patients cancer or hematologic disorders. policies processes within may act as model other clinical areas. breadth experience access to wide knowledge base exists that will ensure appropriate development consideration practical implications REMS. NCCN is uniquely positioned assume leadership role this process given its status...
The paradigm shift in health care toward value-based reimbursement has brought emphasis to providing better quality of patients with chronic diseases, including cancer. In accordance patients, there been a growing interest evaluating life through patient-reported outcomes (PROs). revised Edmonton Symptom Assessment Scale (ESAS-r) is tool that can be used assess PROs and validated for use This initiative sought this standard assessment acquire concerning symptom burden from prescribed oral...
To assess the effectiveness, safety, and cost of empiric treatment febrile neutropenia before after implementing an algorithm in which voriconazole was substituted for liposomal amphotericin B (L-AmB).Retrospective cohort analysis.An 850-bed tertiary care hospital, is also a referral site patients with acute leukemia.Fifty-five adult who started antifungal therapy between January 1, 2002, December 31, 2003, encompassing 58 episodes (defined as hospitalization during administered).Medical...
Oral anticancer medications (OAMs) have changed the oncology treatment landscape for patients and clinicians. OAM use is growing annually, accounting 40%–50% of new cancer treatments in development (U.S. Food Drug Administration, 2021). Shifting from a controlled clinical setting to patient’s home has advantages paired with potential challenges patient healthcare team.
Disparities in cancer treatment, including access to medications, continue exist. Rising drug prices and shortages are 2 causes of inequitable treatment. This article introduces pilot outcomes for a solution improve medications while also decreasing medication waste. Cancer repositories an innovative patient-centered model where donations unused from patients repurposed provided who most vulnerable disproportionately harmed by financial toxicity. demonstrates efficiency sustainability that...
Background: Oral anticancer agents (OAAs) transformed cancer care for patients, extending survival and delaying progression in certain cases. There are multiple pharmacy-driven models to improve patient knowledge adherence OAAs. However, a lack of measurable key performance indicators (KPIs) has limited the adoption, implementation, maintenance these models. The objective this study was identify set KPIs, their metrics, target values that indicated improved through an OAA program. Methods: A...
Improvements in chronic myeloid leukemia (CML), lymphocytic (CLL), and multiple myeloma (MM) treatment options have increased the 5-year survival rates for patients with these hematologic malignancies. In addition to cancer management, may need help manage conditions (MCC). The overall objective of this study is examine impact implementation a model that coordinates care between oncology primary pharmacists people taking an oral anti-cancer agent (OAAs) medications comorbid conditions. This...
A focus on oral medications for patients receiving care from both oncologists and primary providers elicits an opportunity improvement in patient outcomes. The purpose of this pilot study was to explore the feasibility appropriateness a comprehensive medication review (CMR) by pharmacist population with cancer chronic conditions.Adult who received at Michigan Medicine, active systemic treatment, had comorbid condition diabetes, hypertension, heart failure, depression, and/or anxiety were...
The goal of this study is to determine barriers and facilitators the implementation medication adherence interventions support cancer patients taking novel, targeted oral anticancer agents (OAAs).We conducted qualitative interviews using a semi-structured guide from Consolidated Framework for Implementation Research (CFIR). We used purposive sampling identify clinicians (physicians, pharmacists, nurse practitioners, nurses) administrators (leadership medicine, pharmacy, nursing) who...
Patient-reported outcome measures (PROMs) for symptom monitoring during cancer therapy have been shown to a positive impact on outcomes. These findings primarily patients receiving intravenous chemotherapy. In addition, there is known discordance between physician reporting of symptoms and patient self-report. This initiative sought describe patient-reported burden medication adherence indicate the degree PROM results being discussed with provider as indicated by documentation in medical...